메뉴 건너뛰기




Volumn 26, Issue 11, 2015, Pages 2341-2346

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors

Author keywords

Advanced cancer; angiogenesis; nintedanib; phase I trial; Plk1; volasertib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NINTEDANIB; VOLASERTIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PTERIDINE DERIVATIVE;

EID: 84947772543     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv354     Document Type: Article
Times cited : (33)

References (22)
  • 1
    • 0035235736 scopus 로고    scopus 로고
    • Mitotic kinases as regulators of cell division and its checkpoints
    • Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21-32.
    • (2001) Nat Rev Mol Cell Biol , vol.2 , pp. 21-32
    • Nigg, E.A.1
  • 2
    • 2942615282 scopus 로고    scopus 로고
    • Polo-like kinases and the orchestration of cell division
    • Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
    • (2004) Nat Rev Mol Cell Biol , vol.5 , pp. 429-440
    • Barr, F.A.1    Sillje, H.H.2    Nigg, E.A.3
  • 3
    • 33645316142 scopus 로고    scopus 로고
    • Targeting polo-like kinase 1 for cancer therapy
    • Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
    • (2006) Nat Rev Cancer , vol.6 , pp. 321-330
    • Strebhardt, K.1    Ullrich, A.2
  • 4
    • 0038624074 scopus 로고    scopus 로고
    • Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
    • Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 5789-5794
    • Liu, X.1    Erikson, R.L.2
  • 5
    • 0037132736 scopus 로고    scopus 로고
    • Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells
    • Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94: 1863-1877.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1863-1877
    • Spänkuch-Schmitt, B.1    Bereiter-Hahn, J.2    Kaufmann, M.3    Strebhardt, K.4
  • 6
    • 65649105075 scopus 로고    scopus 로고
    • BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity
    • Rudolph D, Steegmaier M, Hoffmann M et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.
    • (2009) Clin Cancer Res , vol.15 , pp. 3094-3102
    • Rudolph, D.1    Steegmaier, M.2    Hoffmann, M.3
  • 7
    • 84900540918 scopus 로고    scopus 로고
    • A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies
    • Lin C-C, Su W, Yen C-J et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 2014; 110: 2434-2440.
    • (2014) Br J Cancer , vol.110 , pp. 2434-2440
    • Lin, C.-C.1    Su, W.2    Yen, C.-J.3
  • 8
    • 84655164874 scopus 로고    scopus 로고
    • A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    • Schöffski P, Awada A, Dumez H et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-186.
    • (2012) Eur J Cancer , vol.48 , pp. 179-186
    • Schöffski, P.1    Awada, A.2    Dumez, H.3
  • 9
    • 84255215015 scopus 로고    scopus 로고
    • Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
    • Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011; 4: 43-58.
    • (2011) Onco Targets Ther , vol.4 , pp. 43-58
    • Ballas, M.S.1    Chachoua, A.2
  • 10
    • 0036984640 scopus 로고    scopus 로고
    • Role of angiogenesis in tumor growth and metastasis
    • Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
    • (2002) Semin Oncol , vol.29 , pp. 15-18
    • Folkman, J.1
  • 11
    • 84880212274 scopus 로고    scopus 로고
    • BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
    • Rolfo C, Raez LE, Bronte G et al. BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013; 22: 1081-1088.
    • (2013) Expert Opin Investig Drugs , vol.22 , pp. 1081-1088
    • Rolfo, C.1    Raez, L.E.2    Bronte, G.3
  • 12
    • 84892967581 scopus 로고    scopus 로고
    • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
    • Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155.
    • (2014) Lancet Oncol , vol.15 , pp. 143-155
    • Reck, M.1    Kaiser, R.2    Mellemgaard, A.3
  • 13
    • 84886393615 scopus 로고    scopus 로고
    • Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy
    • Hanna NH, Kaiser R, Sullivan RN et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31(15s): 8034.
    • (2013) J Clin Oncol , vol.31 , Issue.15 , pp. 8034
    • Hanna, N.H.1    Kaiser, R.2    Sullivan, R.N.3
  • 14
    • 84947787434 scopus 로고    scopus 로고
    • Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC)
    • Kristensen G, Harter P, Trédan O et al. Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC). J Clin Oncol 2014; 32(15s): 5556.
    • (2014) J Clin Oncol , vol.32 , Issue.15 , pp. 5556
    • Kristensen, G.1    Harter, P.2    Trédan, O.3
  • 15
    • 74949090791 scopus 로고    scopus 로고
    • Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors
    • Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 311-319.
    • (2010) Clin Cancer Res , vol.16 , pp. 311-319
    • Mross, K.1    Stefanic, M.2    Gmehling, D.3
  • 16
    • 84891835786 scopus 로고    scopus 로고
    • Molecular-targeted agents combination therapy for cancer: developments and potentials
    • Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 2014; 134: 1257-1269.
    • (2014) Int J Cancer , vol.134 , pp. 1257-1269
    • Li, F.1    Zhao, C.2    Wang, L.3
  • 17
    • 82055198571 scopus 로고    scopus 로고
    • Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
    • Bousquet G, Alexandre J, Le Tourneau C et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011; 105: 1640-1645.
    • (2011) Br J Cancer , vol.105 , pp. 1640-1645
    • Bousquet, G.1    Alexandre, J.2    Le Tourneau, C.3
  • 18
    • 77958038695 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
    • Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-2833.
    • (2010) Mol Cancer Ther , vol.9 , pp. 2825-2833
    • Okamoto, I.1    Kaneda, H.2    Satoh, T.3
  • 19
    • 0003808139 scopus 로고    scopus 로고
    • Version 3.0, DCTD, NCI, NIH, DHHS (20 May 2014, date last accessed)
    • Common Terminology Criteria For Adverse Events (CTCAE). Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (20 May 2014, date last accessed).
    • Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events
  • 20
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 21
    • 84867582561 scopus 로고    scopus 로고
    • Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    • Brell JM, Krishnamurthi SS, Rath L et al. Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 547-553.
    • (2012) Cancer Chemother Pharmacol , vol.70 , pp. 547-553
    • Brell, J.M.1    Krishnamurthi, S.S.2    Rath, L.3
  • 22
    • 78650953061 scopus 로고    scopus 로고
    • A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
    • Davies JM, Dhruva NS, Walko CM et al. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer 2011; 71: 151-155.
    • (2011) Lung Cancer , vol.71 , pp. 151-155
    • Davies, J.M.1    Dhruva, N.S.2    Walko, C.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.